The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
AACR 2017 | Poster 2770/2 – BCL-2 overexpression is a predictive biomarker for the combination of ABT-199 with chemotherapy in Diffuse Large B-Cell Lymphoma cell lines
On Monday 3rd April during this year's American Association for Cancer Research (AACR) annual meeting, a poster (2770 / 2) by Ian McConnell, from VCU Massey Cancer Center, Richmond, VA, et al. titled “Bcl-2 overexpression is a predictive biomarker for the combination of ABT-199 with chemotherapy in diffuse large B-cell lymphoma cell lines” was presented.
The group hypothesized that BCL-2 overexpression correlates with sensitivity to ABT-199 plus chemotherapy in DLBCL. To test this, they analyzed the effect of ABT-199 in four different DLBCL cell lines with different levels of BCL-2 expression: (from highest to lowest) CARNAVAL, OCI-ly18, SU-DHL-4, and SU-DHL-8.
Key Highlights:
- CARNAVAL was the most sensitive (IC50 = ~7nM); SU-DHL-8 was the least sensitive (IC50 = 10µM)
- The remaining 2 cell lines displayed intermediate sensitivity (45.9nM for OCI-ly18 and 2.6µM for SU-DHL-4)
- In CARNAVAL cells, the combination of either etoposide or doxorubicin chemotherapy with ABT-199 led to a significant reduction in cell viability at 48hrs versus each single agent alone
- This was associated with induction of apoptosis measured by Annexin-V/PI, caspase-3, and PARP cleavage, an increase in γ-H2AX, and decrease in Mcl-1
- ABT-199 did not enhance the activity of chemotherapy in SU-DHL-8 cells
The poster was concluded by stating that these preclinical results support the use of BCL-2 overexpression as a predictive biomarker, enabling more accurate selection of DLBCL patients who are likely to benefit from combining ABT-199 with chemotherapy.
References